TBPH supply chain intelligence for Theravance Biopharma, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ORANY | ORANY | 72% | graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or divest an asset that we designate as outside our core business, where we believe the … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or di… |
| RPRX | Royalty Pharma plc | 72% | Reciprocal relationship from RPRX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: . As a result of our significant scale and highly flexible business model, w… |
| SNYNF | Sanofi | 72% | graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or divest an asset that we designate as outside our core business, where we believe the … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: graphic reach, and/or to manage the financial risk associated with the program. Alternatively, we may monetize or di… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VIATRIS | VIATRIS | 92% | Under the terms of the Viatris Agreement, which included the delivery by the Company of a license to Viatris to develop and commercialize revefenacin, Viatris was responsible for reimbursement of the… |
| LUPIN-PHARMACEUTICALS-INC | LUPIN-PHARMACEUTICALS-INC | 90% | As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI | ORBICULAR-PHARMACEUTICAL-TECHNOLOGIES-PRIVATE-LI | 90% | As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| QILU-PHARMACEUTICALS-CO-LTD | QILU-PHARMACEUTICALS-CO-LTD | 90% | As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| TEVA-PHARMACEUTICALS-INC | TEVA-PHARMACEUTICALS-INC | 90% | As of February 28, 2026, the Company has settled all litigation with Accord Healthcare, Inc.; Cipla USA, Inc. and Cipla Limited; Eugia Pharma Specialties Ltd.; Lupin Pharmaceuticals, Inc.; Orbicular … |
| MANKIND-PHARMA-LTD | MANKIND-PHARMA-LTD | 80% | The patent litigation against the one remaining generic company, Mankind Pharma Ltd., along with certain affiliates, remains pending. |
| ORANY | ORANY | 72% | and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TBPH graph: and examining the medical necessi… |
| SNYNF | Sanofi | 72% | and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in ord… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from SNYN… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TBPH-DEBT | Debt stack $40.5M | 90% | Market cache reports total debt of $40.5M. |
| TBPH-DEBT-12897 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-06-30. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TBPH-OWNER-MADISON-AVENUE-PARTNERS-LP | Madison Avenue Partners, LP | 90% | 13F overlay lists Madison Avenue Partners, LP as top holder; 174 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 |